Approved
consistent with clarifications in FDA memos (3) of 6-12- 02. When
FDA publishes the notice of approval for this collection, it shall
include the public burden statement in the notice. For future
guidances that impose information collections and when changes are
made to existing guidances, FDA shall include the OMB number and
burden statement in the guidance. FDA does not need to include the
expiration date in these cases.
Inventory as of this Action
Requested
Previously Approved
08/31/2005
08/31/2005
06/30/2002
86
0
114
6,480
0
9,000
0
0
0
This guidance is intended to
articulate how FDA plans to work with sponsors to achieve expedited
development and rapid review of new drugs intended to treat serious
or life-threatening conditions and that demonstrate the potential
to address unmet medical needs for the condition. The guidance also
meets the requirements of section 112 of the Food and Drug
Administration Modernization Act of 1997, which amended the Federal
Food, Drug and Cosmetic Act (21 U.S.C. 351 et seq.) by adding new
section 506 ("Fast Track Products").
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.